Pipeline – TAK-007

Overview^1-6

- TAK-007 is a cryopreserved CD19-targeted CAR-NK therapy

- Cord blood offers an allogeneic, off-the-shelf source of NK cells

- NK cells are highly cytotoxic effectors, killing their targets in a non-antigen specific manner

Mechanism of Action^1-6

- Retrovirus technology is used to enhance NK cell activity with the following characteristics:

• CD19 is added to increase CAR NK cell specificity for B cell malignancies
• NK cell activation leads to the secretion of tumoricidal molecules such as granzyme and perforin
• IL15 is added to prolong the viability of the NK cells in the recipient

TAK-007 is an investigational therapy. Clinical efficacy and safety have not yet been established.

CAR, chimeric antigen receptor; CASP9, caspase-9; CB, cord blood; CD19, cluster of differentiation 19; HLA, human leukocyte antigens; IL-15, interleukin 15; KIR, killer immunoglobulin-like recptors; NK, natural killer.

Clinical Trials

Study Name

A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

References

1. Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553. doi:10.1056/NEJMoa1910607

2. Liu E, Tong Y, Dotti G, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32(2):520-531. doi:10.1038/leu.2017.226

3. Takeda Oncology. Accessed April 2023.

4. Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59:102975. doi:10.1016/j.ebiom.2020.102975

5. Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol. 2018;51:146-153. doi:10.1016/j.coi.2018.03.013

6. Takeda press release (Nov 21, 2019). Takeda Oncology: Innovative Cell Therapies and New Frontiers in Immuno-Oncology. [online] Available at Web link Accessed April 2023.

Disclaimers

*Under licensing agreement and in collaboration with MD Anderson Cancer Center.